The correspondence deals with the treatment of community-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA).[2][8] According to the correspondence, the author's seminar on community-acquired pneumonia did not deal sufficiently with new drugs specifically approved for MRSA infections.[2][8] In the treatment of MRSA pneumonia, vancomycin and linezolid have traditionally been used as the main therapeutic options.[2][8] Linezolid exhibits better lung tissue penetration and better availability at the tissue level compared to vancomycin.[8] Some randomized clinical trials suggest that linezolid may be more effective than vancomycin in terms of clinical and microbiological response in the treatment of MRSA pneumonia.[2][8] The correspondence points to the need to consider other anti-MRSA options, including telavancin, which could be a good alternative in patients without underlying renal failure.[2]